Company news

Biocon Limited news in 2025

Biocon Limited's news releases, calls and decks from 2025, newest first.

View company

Press Release Dec 23 2025

December 23, 2025

Biocon Limited Press Release Dec 23 2025

December 22, 2025

Press Release Dec 17 2025

December 17, 2025

Biocon Limited Press Release Dec 17 2025

December 16, 2025

Press Release Dec 15 2025

December 15, 2025

Biocon Limited Press Release Dec 15 2025

December 14, 2025

Press Release Dec 13 2025

December 13, 2025

Press Release Dec 11 2025

December 11, 2025

Press Release Dec 06 2025

December 6, 2025

Biocon Limited Press Release Dec 06 2025

December 5, 2025

Press Release Dec 02 2025

December 2, 2025

Biocon Limited Press Release Dec 02 2025

December 1, 2025

Press Release Nov 11 2025

November 11, 2025

Press Release Oct 23 2025

October 23, 2025

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®

October 23, 2025

Biocon Limited Press Release Oct 23 2025

October 22, 2025

Press Release Oct 16 2025

October 16, 2025

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

October 16, 2025

Press Release Oct 01 2025

October 1, 2025

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars

October 1, 2025

Biocon Limited Press Release Oct 01 2025

September 30, 2025

Press Release Sep 18 2025

September 18, 2025

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases

September 18, 2025

Press Release Sep 17 2025

September 17, 2025

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars

September 17, 2025

Press Release Sep 12 2025

September 12, 2025

Press Release Sep 11 2025

September 11, 2025

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey

September 10, 2025

Press Release Aug 07 2025

August 7, 2025

Press Release Jul 28 2025

July 28, 2025

Press Release Jul 23 2025

July 23, 2025

Press Release Jul 16 2025

July 16, 2025

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States

July 15, 2025

Press Release Jul 07 2025

July 7, 2025

Biocon Limited Press Release Jul 07 2025

July 6, 2025

Press Release Jul 03 2025

July 3, 2025

Biocon Limited Press Release Jul 03 2025

July 2, 2025

Press Release Jun 30 2025

June 30, 2025

Biocon Limited Press Release Jun 30 2025

June 29, 2025

Press Release Jun 27 2025

June 27, 2025

Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025

June 27, 2025

Biocon Limited Press Release Jun 27 2025

June 26, 2025

Press Release Jun 24 2025

June 24, 2025

Biocon Limited Press Release Jun 24 2025

June 23, 2025

Press Release Jun 20 2025

June 20, 2025

Press Release Jun 09 2025

June 9, 2025

Press Release May 08 2025

May 8, 2025

Press Release May 05 2025

May 5, 2025

Biocon Limited Press Release May 05 2025

May 4, 2025

Press Release Apr 15 2025

April 15, 2025

Older news releases →

Decks in 2025